Skip to main content
. 2020 Oct 19;12(10):661. doi: 10.3390/toxins12100661

Table 9.

Pulmonary related adverse events in Study 1 in ≥3% of patients in any group.

Adverse Event Placebo
(n = 36)
OnabotA 240 U (n = 36) OnabotA 360 U (n = 36)
Overall 11 (30.6%) 8 (22.9%) 16 (43.2%)
Nasopharyngitis 2 (5.6%) 3 (8.6%) 6 (16.2%)
Bronchitis 0 (0.0%) 1 (2.9%) 2 (5.4%)
Upper respiratory tract infection 2 (5.6%) 0 (0.0%) 2 (5.4%)
Oropharyngeal pain 0 (0.0%) 2 (5.7%) 1 (2.7%)